Pilot study indicates positive treatment for alopecia

28 Oct 2016

A US pilot study investigating the use of oral JAK1/2 inhibitor ruxolitinib in the treatment of patients with moderate to severe alopecia areata has indicated a 75% growth in scalp hair regrowth.

Researchers observed 12 patients with alopecia areata after the treatment of oral ruxolitinib at 20mg twice per day for three to six months, followed by a three-month follow-up of the drug’s effects. Nine patients had an average hair regrowth of 92% at the end of the treatment.

The researchers published their findings in the Journal of Clinical Investigation Insight, and concluded that, “Larger randomised controlled trials are needed to further assess the safety and efficacy of ruxolitinib in the treatment of alopecia areata.”


Log-in to post a comment